TON - August 2020, Vol 13, No 4
The small molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. The responses were durable, with a median duration of response of 9.03 months.
The thyroid is a butterfly-shaped endocrine gland that produces hormones essential in maintaining normal heart rate, blood pressure, body temperature, and metabolism. Thyroid cancer represents only 2.9% of new cancer cases annually in the United States but occurs approximately 3 times as often in women as in men.1,2 The following information about thyroid cancer may prove helpful.
Early results from the phase 2 TheraP clinical trial show that the targeted radiation therapy 177Lutetium PSMA-617 (Lu-PSMA) significantly improved prostate-specific antigen (PSA) response compared with standard cabazitaxel in men with metastatic castration-resistant prostate cancer (CRPC) that progressed after docetaxel therapy.
Oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting (Shore ND, et al. N Engl J Med. 2020;382:2187-2196).
Breast cancer doctors got it right a long time ago when they began characterizing malignancies with classifications such as hormone-receptor and HER2 status, according to Alexander Spira, MD, PhD, FACP, Medical Oncologist, Virginia Cancer Specialists, Fairfax.
Social distancing, stay-at-home orders, and “the new normal.” We are all adapting to the changes brought about by COVID-19, but what does it mean for cancer care? At the virtual 2020 Community Oncology Alliance (COA) Community Oncology Conference, Bo Gamble, Director, Strategic Practice Initiatives, COA, asked a panel of experts to predict how the current climate will shape challenges for community oncologists in the future.
Updated results of the phase 3 CASPIAN clinical trial continue to show that durvalumab (Imfinzi) added to standard chemotherapy improves overall survival (OS) for patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC), according to a presentation at the ASCO 2020 virtual annual meeting.
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma
A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
According to long-term follow-up data presented at the ASCO 2020 virtual annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).
Page 1 of 3
Results 1 - 10 of 27
Results 1 - 10 of 27